Green Cross Secures Mid-to-Long-Term U.S. Growth Foundation with Alyglo
Green Cross (006280), a leading biopharmaceutical firm, has laid a robust groundwork for sustained expansion in the U.S. market through its innovative blood product Alyglo, as highlighted by Heungkuk